Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) will release its financial results for Q2 2021 on August 10, 2021, prior to market opening. A conference call will follow at 8:30 a.m. ET to discuss these results and provide a business update. The company is focused on innovative therapeutics for rare seizure disorders, with Ganaxolone, a modulator of GABAA receptors, being a key product. It has completed a Phase 3 trial for CDKL5 deficiency disorder and is currently pursuing trials for tuberous sclerosis complex and refractory status epilepticus.
- Completion of the first-ever Phase 3 pivotal trial for Ganaxolone in children with CDKL5 deficiency disorder.
- Ongoing clinical trials for Ganaxolone in tuberous sclerosis complex and refractory status epilepticus.
- None.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the second quarter ended June 30, 2021 before the market opens on August 10, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2021, to provide a business update and discuss the financial results.
Tuesday, August 10: 8:30 a.m. Eastern Time
Domestic: (833) 979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3194348/D7BBD3D17DC6E8447B1781C07F60BE82
Conference ID: 4254409
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005397/en/
FAQ
When will Marinus Pharmaceuticals release its Q2 2021 financial results?
What is the conference call schedule for Marinus Pharmaceuticals?
What is Ganaxolone and its significance for Marinus Pharmaceuticals?
What clinical trials is Marinus Pharmaceuticals currently conducting?
